» Articles » PMID: 37405477

A Risk Prognostic Model for Patients with Esophageal Squamous Cell Carcinoma Basing on Cuproptosis and Ferroptosis

Overview
Specialty Oncology
Date 2023 Jul 5
PMID 37405477
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cuproptosis, a form of copper-dependent programmed cell death recently presented by Tsvetkov et al., have been identified as a potential therapeutic target for refractory cancers and ferroptosis, a well-known form describing iron-dependent cell death. However, whether the crossing of cuproptosis-related genes and ferroptosis-related genes can introduce some new idea, thus being used as a novel clinical and therapeutic predictor in esophageal squamous cell carcinoma (ESCC) remains unknown.

Methods: We collected ESCC patient data from the Gene Expression Omnibus and the Cancer Genome Atlas databases and used Gene Set Variation Analysis to score each sample based on cuproptosis and ferroptosis. We then performed weighted gene co-expression network analysis to identify cuproptosis and ferroptosis-related genes (CFRGs) and construct a ferroptosis and cuproptosis-related risk prognostic model, which we validated using a test group. We also investigated the relationship between the risk score and other molecular features, such as signaling pathways, immune infiltration, and mutation status.

Results: Four CFRGs (MIDN, C15orf65, COMTD1 and RAP2B) were identified to construct our risk prognostic model. Patients were classified into low- and high-risk groups based on our risk prognostic model and the low-risk group showed significantly higher survival possibilities (P < 0.001). We used the "GO", "cibersort" and "ESTIMATE" methods to the above-mentioned genes to estimate the relationship among the risk score, correlated pathways, immune infiltration, and tumor purity.

Conclusion: We constructed a prognostic model using four CFRGs and demonstrated its potential clinical and therapeutic guidance value for ESCC patients.

Citing Articles

Single-Cell Sequencing and Transcriptome Analysis Explored Changes in Midnolin-Related Immune Microenvironment and Constructed Combined Prognostic Model for Pancreatic Cancer.

Guan X, Xu L, Liu J, Fei H, Wang C J Inflamm Res. 2025; 18:2975-2990.

PMID: 40026303 PMC: 11872096. DOI: 10.2147/JIR.S503326.


Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.

Imam M, Ji J, Zhang Z, Yan S Front Pharmacol. 2025; 15:1493188.

PMID: 39867656 PMC: 11757020. DOI: 10.3389/fphar.2024.1493188.


Predicting Outcomes in Esophageal Squamous Cell Carcinoma Using scRNA-Seq and Bulk RNA-Seq: A Model Development and Validation Study.

Zhang J, Song S, Li Y, Gong A Cancer Med. 2025; 14(2):e70617.

PMID: 39840762 PMC: 11751878. DOI: 10.1002/cam4.70617.

References
1.
Song Q, Zhou R, Shu F, Fu W . Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer. Front Immunol. 2022; 13:958368. PMC: 9386055. DOI: 10.3389/fimmu.2022.958368. View

2.
Gao X, Liu Q, Chen X, Chen S, Yang J, Liu Q . Screening of tumor grade-related mRNAs and lncRNAs for Esophagus Squamous Cell Carcinoma. J Clin Lab Anal. 2021; 35(6):e23797. PMC: 8183932. DOI: 10.1002/jcla.23797. View

3.
Qiu H, Zheng L, Tang W, Yin P, Cheng F, Wang L . Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. Clin Biochem. 2014; 47(7-8):612-7. DOI: 10.1016/j.clinbiochem.2013.12.023. View

4.
He S, Xu J, Liu X, Zhen Y . Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B. 2021; 11(11):3379-3392. PMC: 8642427. DOI: 10.1016/j.apsb.2021.03.008. View

5.
Elpek G, Gelen T, Aksoy N, Erdogan A, Dertsiz L, Demircan A . The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol. 2001; 54(12):940-4. PMC: 1731336. DOI: 10.1136/jcp.54.12.940. View